Guardant Health (GH) Co-ceo Amirali Talasaz Buys $598K of Stock

Talasaz's Share Purchase Highlights Confidence

Amirali Talasaz, Co-Chief Executive Officer of Guardant Health, Inc. (NasdaqGS: GH), purchased 143,028 shares on June 29, 2026, at a price of $4.18 per share, totaling approximately $597,857. This transaction reflects a significant personal investment in the company as it prepares for its upcoming earnings report.

Talasaz Maintains Strong Stake

This purchase adds to Talasaz's existing holdings, indicating continued confidence in Guardant Health's future. Prior to this transaction, he had 111,804 shares, which he also acquired on June 26, 2026. With this latest buy, Talasaz shows commitment to the company's growth and stability in the face of market fluctuations.

Institutional Support for Guardant Health

While no other funds reported recent activity regarding Guardant Health, the company has received positive analyst ratings recently. There is a healthy belief among analysts about the firm’s prospects, as evidenced by multiple strong buy recommendations from various firms.

Stock Performance Context

As of the publication date, Guardant Health shares are priced at $150.03. This is a significant drop from their 52-week high of $183.51, suggesting the stock is currently undervalued. Investors will be watching closely as the company approaches its next earnings date, scheduled for October 28, 2026.

Recent Earnings

For the year, Guardant Health reported revenue of approximately $1.18 billion, showing a growth rate of 44.3%. However, the company has not reached profitability, with an EPS of -$3.52 and a net margin of -38.33%. These figures underline the challenges the company faces but also the potential for growth as it develops its innovative cancer diagnostics.

Analysts Set New Price Targets

Analysts have maintained positive sentiments towards Guardant Health. On October 13, 2026, Morgan Stanley reaffirmed its Overweight rating and raised its price target to $200. Similarly, Barclays kept its Overweight rating with a target of $220, indicating widespread confidence in the company's recovery and future performance.

What Guardant Health, Inc. Does

Guardant Health, Inc. is a precision oncology company based in Palo Alto, California. It specializes in blood and tissue tests that help detect and monitor cancer. Its innovative products, like the Guardant360 tests, play a crucial role in advancing cancer care, making its recent insider purchase a notable signal of leadership confidence.

What's Ahead for Guardant Health, Inc.

Investors are poised to see how Guardant Health navigates the next earnings report on October 28, 2026. While the insider activity indicates a strong belief in the company's direction, the upcoming financials will be crucial in shaping market perceptions. As always, 13F filings reflect past positions and may not accurately represent current holdings.